Canopy Growth (CGC) Q4 2026 earnings review
Profitability Target in Sight, but Core Segments Diverge
Canopy Growth finished FY26 with a 10% YoY net revenue bump in Q4, but the underlying segment dynamics are violently shifting. While Canada Medical is accelerating and International operations have reversed their past failures, the Canada Adult-Use segment has hit a brick wall, decelerating to a mere 1% growth. Furthermore, reported gross margins were crushed by a $10.7M inventory write-down linked to the recent MTL Cannabis acquisition. However, aggressive cost-cutting has significantly narrowed the Adjusted EBITDA loss to $6.3M, and management's promise of achieving positive Adjusted EBITDA in FY27 appears structurally plausible, provided they can halt the bleeding in Storz & Bickel and maintain medical momentum.
🐂 Bull Case
With the MTL Cannabis acquisition closed, Canopy has cemented itself as Canada's leading medical cannabis provider by revenue. Q4 medical sales accelerated to 27% YoY growth, serving as the company's most reliable growth engine.
Canopy ended FY26 with a net cash position of $131.3M, a staggering $303.9M improvement from the $172.6M net debt position a year ago, eliminating near-term liquidity survival risks.
🐻 Bear Case
Canada Adult-Use growth rapidly decelerated throughout FY26: from 43% in Q1, to 30% in Q2, to 8% in Q3, down to just 1% in Q4. Early innovation tailwinds (vapes, pre-rolls) have clearly run their course.
Despite the launch of the new VEAZY vaporizer, Storz & Bickel sales declined 14% YoY in Q4. Consumer economic uncertainty and U.S. tariffs are compressing both volume and margins (Q4 GM dropped 900 bps to 27%).
⚖️ Verdict: ⚪
Neutral. Management deserves immense credit for fixing the balance sheet and stripping out SG&A costs. However, the severe deceleration in the Adult-Use segment and the persistent decline in Storz & Bickel raise real questions about the sustainability of top-line growth needed to actually achieve the promised FY27 profitability.
Key Themes
Medical Ascendancy and MTL Cannabis Integration
Canada Medical revenue accelerated sharply, posting 27% YoY growth to $25.3M in Q4, up from 15% growth in Q3. This is Canopy's crown jewel. The recently completed acquisition of MTL Cannabis strategically positions the company as the #1 medical player in Canada. The integration is expected to fuel a broader portfolio—such as the newly launched Spectrum Reserve premium brand—and supply high-quality flower to the rebounding European markets.
MTL Acquisition Immediately Triggers Write-Downs
While management touts MTL Cannabis as a highly accretive, cash-generating asset that will improve gross margins, the immediate reality in Q4 contradicts the clean narrative. Canopy incurred $10.7M of inventory charges this quarter, explicitly citing a review of overall Cannabis segment inventory levels following the MTL acquisition. This massive charge destroyed Q4 reported Cannabis gross margins, sinking them to just 7%.
International Execution Reversing Course
International markets cannabis net revenue reversed its prior negative trajectory, surging 68% YoY to $8.6M in Q4. Management successfully addressed the severe supply chain constraints and quality issues that plagued European deliveries earlier in the fiscal year (which caused a 39% YoY drop back in Q2). If they can maintain consistent EU GMP supply from the Smiths Falls and MTL facilities, Europe represents a massive growth lever for FY27.
Storz & Bickel Deflated by U.S. Macro and Tariffs
The vaporizer unit continues to disappoint. Q4 net revenue fell 14% YoY to $16.8M, mirroring its full-year decline of 14%. Furthermore, Q4 gross margins compressed significantly from 36% to 27%. Management explicitly blamed lapping strong prior-year sales, continued consumer economic uncertainty, and crucially, increased tariffs on imports into the United States. The launch of the affordable VEAZY device has not been enough to reverse the segment's contraction.
Relentless SG&A Cost Discipline
The path to positive EBITDA is currently paved entirely by cost cuts, not margin expansion. SG&A for the full year decreased 6% ($9.6M reduction). Q4 Adjusted EBITDA loss narrowed 32% to $6.3M. With headcount reductions, professional fee cuts, and lower IT costs fully baked into the run rate, the baseline operating expenses have fundamentally stepped down, giving management structural leverage heading into FY27.
Adult-Use Innovation Tailwinds Exhausted
The aggressive deceleration of the Canada Adult-Use segment (from +43% YoY in Q1 to +1% YoY in Q4) strongly suggests that the initial boost from launching new All-In-One vaporizers and infused pre-roll joints (PRJs) early in FY26 was a one-time pipeline fill rather than sustained market share capture. Continued growth here will require another cycle of heavy innovation or deep price discounting, either of which will pressure margins.
Other KPIs
Accelerating/Improving from 19% in Q4 FY25. This metric excludes the brutal $9.9M in restructuring/inventory write-downs and $0.8M of inventory step-up flow-through from the MTL acquisition. While GAAP gross margin was ugly (12%), the adjusted figure proves that unit-level economics on actual sales are improving.
A massive improvement from the -$176.6M outflow in FY25. This 61% reduction in cash burn was driven by lower interest expenses (following strategic debt prepayments), structural SG&A reductions, and disciplined working capital management. The company is finally approaching cash flow neutrality.
Narrowed by 49% YoY from -$514.9M in FY25. However, the bottom line is still heavily impacted by non-cash charges, including $67.1M of asset impairment and restructuring costs (mostly tied to Storz & Bickel brand/goodwill impairment) and high other expenses ($101.2M) linked to fair value adjustments.
Guidance
Reversing. Management expects to cross the threshold into positive Adjusted EBITDA during FY27, comparing favorably to the -$20.2M loss in FY26. With integration activities for MTL Cannabis occurring in H1 27, the profitability gains are expected to be heavily weighted toward the second half of the fiscal year.
Accelerating/Stable. While no specific range was provided, management expects top-line growth across segments, driven by successful execution of strategic priorities. This implies they believe they can arrest the decline in Storz & Bickel and re-ignite the stalled Adult-Use segment.
Accelerating. The company projects that the implementation of strengthened cultivation practices, heavily bolstered by the MTL Cannabis acquisition, will drive gross margin expansion. They will need this expansion to achieve their EBITDA targets if Adult-Use pricing power remains constrained.
Key Questions
Adult-Use Deceleration Dynamics
Canada Adult-Use revenue growth decelerated from 43% in Q1 to just 1% in Q4. Was this driven by aggressive competitor pricing, a lack of new product pipeline in H2, or lost retail distribution? How do you re-accelerate this segment in FY27?
Storz & Bickel Tariff Impact
You noted that U.S. import tariffs compressed Storz & Bickel margins. What specific percentage of S&B's COGS is currently subject to these tariffs, and are there viable supply chain shifts or price increases planned to mitigate this in FY27?
MTL Inventory Write-Down
Despite MTL Cannabis being framed as a highly accretive acquisition, you immediately took a $10.7M inventory charge following a review of legacy and acquired inventory. What specific types of inventory were deemed unsalable or overvalued, and are we completely clear of these write-downs heading into Q1 FY27?
European Supply Chain Stability
International revenue surged 68% in Q4 after severe supply constraints earlier in the year. Are your EU GMP facilities currently operating at optimal fill rates, and what level of safety stock are you holding to prevent future out-of-stock events in Germany?